Browsing Tag
renal cell carcinoma
9 posts
Merck and Eisai announce major win as Welireg plus Lenvima delays progression in advanced renal cell carcinoma
Find out how Merck and Eisai’s Welireg + Lenvima combo redefines kidney cancer care after immunotherapy and what this major Phase 3 win means for investors.
October 28, 2025
Kidney and urinary disorders: Understanding major conditions, terminology, and their role in human health
Understand key urinary system diseases including kidney cancer, nephritis, and diabetes-related disorders in this educational health guide.
June 9, 2025
China NMPA accepts NDA for Innovent and HUTCHMED’s sintilimab-fruquintinib combo in advanced renal cell carcinoma
Innovent Biologics (HKEX: 01801) and HUTCHMED (NASDAQ: HCM) secure NDA acceptance in China for sintilimab-fruquintinib in RCC, signaling oncology market shift.
June 5, 2025
Bristol Myers Squibb’s subcutaneous nivolumab shows promise in Phase 3 RCC trial
Bristol Myers Squibb (NYSE: BMY) has announced results from its Phase 3 CheckMate -67T trial, which could revolutionize…
January 29, 2024
Merck’s KEYTRUDA shows 38% reduction in death risk for renal cell carcinoma patients in Phase 3 KEYNOTE-564 trial
Merck & Co., Inc., a global healthcare leader, has recently unveiled groundbreaking results from its Phase 3 KEYNOTE-564…
January 29, 2024
Merck’s WELIREG meets primary endpoint of PFS in Phase 3 RCC trial
Global pharmaceutical leader Merck has announced that WELIREG (belzutifan), its pioneering oral HIF-2α inhibitor, has achieved a critical…
August 20, 2023
LG Chem to acquire US biotech company Aveo Oncology for $566m
LG Chem acquisition of Aveo Oncology : South Korea’s LG Chem has entered into a definitive agreement to…
October 18, 2022
FDA approves Opdivo and Cabometyx combo for advanced kidney cancer treatment
The U.S. Food and Drug Administration (FDA) has officially approved the combination of Bristol Myers Squibb’s Opdivo (nivolumab)…
January 26, 2021
Merck to acquire US biopharma company Peloton Therapeutics in $2.2bn deal
Merck acquisition of Peloton : Pharma giant Merck is set to acquire US biopharma company Peloton Therapeutics in…
July 14, 2019